Upcoming Global Web Symposia
November 15, 2012
11:00 – 12:30 pm EDT
Process related impurity testing and titer determination in bioprocess and production are critical parameters that require rapid turn-around time to results and broad dynamic ranges. Host cell protein impurities are often subject to repeat testing with assays in the production of therapeutic antibodies that has created a situation in which impurity testing (e.g. host cell proteins) can often become a rate limiting step in downstream processing. With an ever-increasing portfolio to support, analytical groups need alternatives to traditional immunoanalytical methods to supply decision making data in a timely fashion. This webinar will focus on the use of automated, nanoliter-scale flow-through technology to address a critical need for improved speed, throughput and reduced repeats in process related impurity testing particularly.
Who Should Attend:
Comparative HCP Testing Using Traditional and Emerging TechnologiesMartha L. Jackson, Senior Research Scientist, Pfizer IncThe Automation of a High Throughput Residual HCP Assay to Support In-Process
Analysis of Monoclonal Antibodies
Jun Hyuk Heo, Biochemist, Biotechnology New and Enabling Technologies (BNET), Merck & Co.
Jun Hyuk Heo
Biologics New & Enabling Technologies (BNET), Merck & Co., Inc.firstname.lastname@example.org
Field Application Scientist
250 First Avenue Suite 300Needham, MA 02494P: 781.972.5400F: 781.972.5425E: email@example.com
biological therapeutic productsbiomarkers & diagnosticsbiopharma strategybioprocess & manufacturingchemistryclinical trials & translational medicinedrug & device safety
drug discovery & developmentdrug targetsgenomicshealthcareit & informaticstechnology & tools for life sciencetherapeutic indications
conferencesReports & Market Researchbarnett educational servicesNews & AdvertisingKnowledge Foundation IT Trainingprofessional services
executive teamtestimonialschi timelinemailing listcareers